Skip to main content
SpringerLink
Log in

Antiplatelet medications in the secondary prevention of ischemic stroke

  • Invited Commentary
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Conclusions

It is difficult to make general statements regarding choices in the medical management of patients with IS given its multiple mechanisms and individual patient variations. It is exceedingly important to manage all vascular risk factors in each patient, especially hypertension. Managing risk factors is as important as, or perhaps more important than, deciding on a prevention medication. Based on the previous discussion, I present my recommendations for antiplatelet secondary prevention of noncardioembolic IS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fields WS, Lemak NA, Frankowski RF, Hardy RJ: Controlled trial of aspirin in cerebral ischemia. Stroke 1977, 8:301–314.

    PubMed  CAS  Google Scholar 

  2. The Canadian Cooperative Study Group: A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian Cooperative Study Group. N Engl J Med 1978, 299:53–59.

    Article  Google Scholar 

  3. Hass WK, Easton JD, Adams HP Jr, et al.: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989, 321:501–507.

    Article  PubMed  CAS  Google Scholar 

  4. Gorelick PB, Richardson D, Kelly M, et al.: Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003, 289:2947–2957.

    Article  PubMed  CAS  Google Scholar 

  5. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329–1339.

    Article  Google Scholar 

  6. Diener HC, Cunha L, Forbes C, et al.: European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143:1–13.

    Article  PubMed  CAS  Google Scholar 

  7. Bousser MG, Eschwege E, Haguenau M, et al.: “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983, 14:5–14.

    PubMed  CAS  Google Scholar 

  8. De Schryver EL, Algra A, van Gijn J: Cochrane review: dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 2003, 34:2072–2080.

    Article  PubMed  CAS  Google Scholar 

  9. Mohr JP, Thompson JL, Lazar RM, et al.: A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001, 345:1444–1451.

    Article  PubMed  CAS  Google Scholar 

  10. Yusuf S, Zhao F, Mehta SR, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494–502.

    Article  PubMed  CAS  Google Scholar 

  11. Steinhubl SR, Berger PB, Mann JT 3rd, et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411–2420.

    Article  PubMed  CAS  Google Scholar 

  12. Diener HC: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, doubleblind, placebo-controlled trial. Lancet 2004, 364:331–337.

    Article  PubMed  CAS  Google Scholar 

  13. CHARISMA: http://www.clinicaltrials.gov/ct/show/NCT00050817. Accessed August 15, 2004.

  14. PRoFESS: http://www.profess-study.com. Accessed August 15, 2004.

  15. SPS3: http://www.clinicaltrials.gov/ct/show/NCT00059306. Accessed August 15, 2004.

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Indiana University School of Medicine, CL 291, 541 Clinical Drive, 46202, Indianapolis, IN, USA

    James D. Fleck MD

Authors
  1. James D. Fleck MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fleck, J.D. Antiplatelet medications in the secondary prevention of ischemic stroke. Curr Neurol Neurosci Rep 5, 1–3 (2005). https://doi.org/10.1007/s11910-005-0015-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-005-0015-2

Keywords

Search

Navigation